Merck has acquired OncoEthix.
Through the acquisition, Merck has gained an investigational, novel oral BET (bromodomain) inhibitor, OTX015, which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors.
|Searching for more deal information? Current Partnering offers the following options:|
Financial terms of the acquisition include an upfront payment of up to $110 million to OncoEthix.
Additional milestone payments of up to $265 million are contingent upon certain clinical and regulatory events being achieved.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2014
Report: Top 50 Big Biotech Partnering and M&A Deal Trends